NRP1 (Neuropilin 1)

Efficacy studies revealed a reduction in mean tumor volume of up to 65% in two independent orthotopic mouse models, with no tumor evident in some of the animals treated with the CCK2p-boundPAPTP construct. Our data suggest that tumor-specific targeting of small molecules may be a promising strategy for precision medicine against PDAC.

On the other hand, NDGA inhibited CBP/p300, decreased H3K27ac levels, and synergized with the EZH2 inhibitor EPZ6438 against PC3 cells. In conclusion, NDGA is a potential epigenetic antineoplastic agent that downregulates EZH2 and H3K27me3 through the NRP1 and PI3K/AKT/mTOR pathways and exerts a synergistic antitumor effect with H3K27ac and EZH2 inhibitors, suggesting that it could be a valuable therapeutic option for prostate cancer.

These findings are highly relevant for clinicians and researchers aiming to enhance ICI effectiveness in solid tumors. Given the ongoing clinical evaluation of iRGD, this simple, non-conjugated strategy offers a feasible and rapidly translatable approach to overcome a key limitation of current ICI therapy and improve outcomes for patients with HCC.

We observed no weight differences between the therapeutic and untreated groups. These promising results should encourage further development of siRNA therapy with this carrier platform.

4-hydroxytamoxifen enhances stemness through the NRP/ERRα pathway to enhance breast cancer cell PTX resistance and metastasis.

Upon mitochondrial localization, the carrier undergoes ROS-triggered degradation, leading to concurrent release of doxorubicin (DOX) and cinnamaldehyde (CA) within mitochondria. This dual release acts synergistically to amplify oxidative stress, collapse ΔΨm, and induce mitochondrial DNA damage, collectively precipitating irreversible apoptosis. This study establishes a programmable platform for developing tumor-penetrating nanotherapeutics with precise subcellular organelle-targeting capabilities.

Our findings demonstrate that NCEH1 accelerates breast cancer progression by modulating NRP1 and activating the TNF-α/NF-κB signalling pathway. Collectively, NCEH1 represents a potential novel biomarker and therapeutic target for breast cancer.

While the antitumor effect of PTX/L-PGDS was comparable to that of Taxol during administration, PTX/L-PGDS-CRGDK exhibited superior tumor suppression compared with Taxol and PTX/L-PGDS. These results suggest that L-PGDS-CRGDK, which can bind relatively large molecules and specifically target tumors, is a promising drug delivery system carrier for the anticancer drug PTX.

We fused the aptamer to short hairpin (sh) RNAs that are specific for Enhancer of zeste homolog 2 (EzH2) or neuropilin-1 (Nrp1), and demonstrated their uptake into CD137+ malignant cells and Tregs, and the subsequent downregulation or EzH2 and Nrp1. This study confirms CD137 as a target for tumor immunotherapy and introduces CD137 aptamer-shRNA chimeras as novel tools to be evaluated for their usefulness in cancer treatment.

The data confirms that the interactions between the c-terminal arginine of these CendR peptides with several key residues, including Asp320, Thr316, Tyr297, and Tyr353, of the b1 binding site of NRP1 are particularly stable. During the MD simulations the three peptides predicted to be strong binders showed negative average free energies of interaction, while the three peptides predicted to bind more weakly showed positive free energies of interaction, providing validation of the docking results.

These findings suggest that NRP1 may regulate radiosensitivity by modulating DNA repair pathways in p53-mutated GBM T98G cells. NRP1 could serve as a potential therapeutic target for improving the response of radioresistant tumors such as GBM.

The 4-year overall survival (OS) and event-free survival (EFS) rates for the entire cohort were 94.4% ± 5.4% (95% CI, 83.8%-100.0%) and 87.7% ± 8.2% (95% CI, 71.6%-100.0%), respectively. Paediatric patients with BPDCN who receive allogeneic HSCT-particularly haploidentical HSCT-during CR following ALL-like induction chemotherapy appear to have favorable outcomes in this limited cohort.